Post

New research · Urology
The Lancet. Oncology · 4d
Cohort studyThe Lancet. Oncology · 2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi … Roger Li
Read paper
UrologyCohort study

Cretostimogene immunotherapy showed complete response in 75% of high-risk bladder cancer.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Mark D Tyson … Roger Li
The Lancet. Oncology · 2026
Background

There are few bladder-sparing treatment options for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer that are effective and have a manageable adverse event profile.

Methods

Received intravesical cretostimogene (1 × 10 12 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.

n = 165 patients
Results
75% [95% CI 66·3-83·2]
the cancer completely disappeared in three-quarters of patients
n = 165 patients
“
Conclusion · 1 of 2

Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events.

Conclusion · 2 of 2

Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
3,216
This many specific enhancers were found in prostate cancer cells, not normal cells.
Cohort Study
HR = 8.02
a high AEN score strongly predicts a higher risk of prostate cancer returning
Cohort Study
75%
PSMA PET/CT detected cancer spread in most prostate cancer patients
Randomized Trial
HR 0·55
adding SBRT to systemic therapy lowered the risk of death
Cohort Study
3.47
diabetes is linked to higher odds of serious bleeding after prostate biopsy
Animal / Preclinical
55.8%
Multidrug resistance found in more than half of cat urine bacteria, limiting treatment options.
Cohort Study
60%
patients had a significant drop in their PSA levels, a prostate cancer marker
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population